CJ Bioscience, Inc. (KOSDAQ:311690)
10,010
-90 (-0.89%)
At close: Apr 2, 2025, 3:30 PM KST
CJ Bioscience Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 8,309 | 64,095 | 49,324 | 62,060 | 13,255 | Upgrade
|
Short-Term Investments | 67,000 | - | - | 18,020 | - | Upgrade
|
Trading Asset Securities | - | - | - | - | 26,020 | Upgrade
|
Cash & Short-Term Investments | 75,309 | 64,095 | 49,324 | 80,080 | 39,275 | Upgrade
|
Cash Growth | 17.50% | 29.95% | -38.41% | 103.89% | 26.35% | Upgrade
|
Accounts Receivable | 72.57 | 160.91 | 303.82 | 233.62 | 99.46 | Upgrade
|
Other Receivables | 623.2 | 178.66 | 523.06 | 474.16 | 257.47 | Upgrade
|
Receivables | 695.77 | 339.57 | 826.88 | 707.78 | 356.93 | Upgrade
|
Inventory | 128.75 | 157.82 | 76.16 | 145.83 | 364.31 | Upgrade
|
Prepaid Expenses | 294.56 | 355.71 | 446.57 | 259.18 | 499.9 | Upgrade
|
Other Current Assets | 333.6 | 262.22 | 258.72 | 362.03 | 592.63 | Upgrade
|
Total Current Assets | 76,762 | 65,210 | 50,932 | 81,555 | 41,089 | Upgrade
|
Property, Plant & Equipment | 8,907 | 12,707 | 14,364 | 9,856 | 19,991 | Upgrade
|
Long-Term Investments | 2 | 2 | 2 | 0 | - | Upgrade
|
Other Intangible Assets | 12,499 | 12,397 | 1,016 | 114.13 | 103.95 | Upgrade
|
Other Long-Term Assets | 1,439 | 811.16 | 25,075 | 24,830 | 12,178 | Upgrade
|
Total Assets | 99,610 | 91,128 | 91,389 | 116,355 | 73,362 | Upgrade
|
Accounts Payable | 220.83 | 122.82 | 336.65 | 287.75 | 708.93 | Upgrade
|
Accrued Expenses | 3,234 | 3,966 | 3,996 | 140.94 | 169.76 | Upgrade
|
Short-Term Debt | 6,365 | 3,971 | 23,588 | 18,441 | - | Upgrade
|
Current Portion of Leases | 1,824 | 1,869 | 1,547 | 1,361 | 205.9 | Upgrade
|
Other Current Liabilities | 6,882 | 4,793 | 5,511 | 3,606 | 1,919 | Upgrade
|
Total Current Liabilities | 18,525 | 14,722 | 34,979 | 23,836 | 3,004 | Upgrade
|
Long-Term Debt | - | - | - | - | 35,081 | Upgrade
|
Long-Term Leases | 1,162 | 2,692 | 3,831 | 4,088 | 479.37 | Upgrade
|
Other Long-Term Liabilities | 2,166 | 2,152 | 2,924 | 577.4 | 314.4 | Upgrade
|
Total Liabilities | 21,853 | 19,633 | 41,734 | 28,502 | 38,878 | Upgrade
|
Common Stock | 6,533 | 4,556 | 2,939 | 2,937 | 1,946 | Upgrade
|
Additional Paid-In Capital | 189,419 | 151,426 | 108,066 | 112,186 | 40,993 | Upgrade
|
Retained Earnings | -119,067 | -85,951 | -62,738 | -28,035 | -8,763 | Upgrade
|
Comprehensive Income & Other | 872.04 | 1,465 | 1,389 | 765.25 | 307.61 | Upgrade
|
Shareholders' Equity | 77,757 | 71,496 | 49,655 | 87,853 | 34,484 | Upgrade
|
Total Liabilities & Equity | 99,610 | 91,128 | 91,389 | 116,355 | 73,362 | Upgrade
|
Total Debt | 9,351 | 8,533 | 28,966 | 23,891 | 35,766 | Upgrade
|
Net Cash (Debt) | 65,958 | 55,562 | 20,357 | 56,190 | 3,509 | Upgrade
|
Net Cash Growth | 18.71% | 172.93% | -63.77% | 1501.15% | -88.44% | Upgrade
|
Net Cash Per Share | 7112.48 | 7844.65 | 3463.50 | 13214.21 | 908.96 | Upgrade
|
Filing Date Shares Outstanding | 9.76 | 9.11 | 5.88 | 5.87 | 3.89 | Upgrade
|
Total Common Shares Outstanding | 9.76 | 9.11 | 5.88 | 5.87 | 3.89 | Upgrade
|
Working Capital | 58,236 | 50,488 | 15,953 | 57,718 | 38,085 | Upgrade
|
Book Value Per Share | 7969.48 | 7845.89 | 8446.71 | 14957.10 | 8859.45 | Upgrade
|
Tangible Book Value | 65,257 | 59,098 | 48,640 | 87,739 | 34,380 | Upgrade
|
Tangible Book Value Per Share | 6688.39 | 6485.40 | 8273.89 | 14937.67 | 8832.74 | Upgrade
|
Land | - | - | - | - | 13,973 | Upgrade
|
Buildings | - | - | - | - | 2,563 | Upgrade
|
Machinery | 14,051 | 13,686 | 10,339 | 4,411 | 3,488 | Upgrade
|
Construction In Progress | - | - | 521.7 | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.